BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 Study

Reuters12-12 21:30

BRIEF-<a href="https://laohu8.com/S/GILD">Gilead</a>: Discontinuation Of Phase 3 STAR-221 Study

Dec 12 (Reuters) - Gilead Sciences Inc GILD.O:

GILEAD: DISCONTINUATION OF PHASE 3 STAR-221 STUDY
GILEAD: DISCONTINUATION DECISION BASED ON RECOMMENDATION FROM INDEPENDENT DATA MONITORING COMMITTEE
GILEAD - IN INTERIM ANALYSIS, COMBINATION OF DOMVANALIMAB PLUS ZIMBERELIMAB & CHEMOTHERAPY DID NOT IMPROVE OS RELATIVE TO NIVOLUMAB PLUS CHEMOTHERAPY
GILEAD: NO CHANGES TO OTHER ONGOING DOMVANALIMAB STUDIES BEYOND UPPER GASTROINTESTINAL PROGRAM
GILEAD - NO NEW SAFETY FINDINGS FOR COMBINATION OF DOMVANALIMAB PLUS ZIMBERELIMAB

Further company coverage: GILD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590350164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590350164","market":"fut","top_or_hot":-1,"title":"BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/GILD\">Gilead</a>: Discontinuation Of Phase 3 STAR-221 Study</title></head><body><p><span>Dec 12 (Reuters)</span><span> - </span>Gilead Sciences Inc <span>GILD.O</span>:</p><ul><li><p>GILEAD: DISCONTINUATION OF PHASE 3 STAR-221 STUDY</p></li><li><p>GILEAD: DISCONTINUATION DECISION BASED ON RECOMMENDATION FROM INDEPENDENT DATA MONITORING COMMITTEE</p></li><li><p>GILEAD -  IN INTERIM ANALYSIS, COMBINATION OF DOMVANALIMAB PLUS ZIMBERELIMAB &amp; CHEMOTHERAPY DID NOT IMPROVE OS RELATIVE TO NIVOLUMAB PLUS CHEMOTHERAPY</p></li><li><p>GILEAD: NO CHANGES TO OTHER ONGOING DOMVANALIMAB STUDIES BEYOND UPPER GASTROINTESTINAL PROGRAM</p></li><li><p>GILEAD - NO NEW SAFETY FINDINGS FOR COMBINATION OF DOMVANALIMAB PLUS ZIMBERELIMAB</p></li></ul><p>Further company coverage: <span>GILD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/GILD\">Gilead</a>: Discontinuation Of Phase 3 STAR-221 Study</title></head><body><p><span>Dec 12 (Reuters)</span><span> - </span>Gilead Sciences Inc <span>GILD.O</span>:</p><ul><li><p>GILEAD: DISCONTINUATION OF PHASE 3 STAR-221 STUDY</p></li><li><p>GILEAD: DISCONTINUATION DECISION BASED ON RECOMMENDATION FROM INDEPENDENT DATA MONITORING COMMITTEE</p></li><li><p>GILEAD -  IN INTERIM ANALYSIS, COMBINATION OF DOMVANALIMAB PLUS ZIMBERELIMAB &amp; CHEMOTHERAPY DID NOT IMPROVE OS RELATIVE TO NIVOLUMAB PLUS CHEMOTHERAPY</p></li><li><p>GILEAD: NO CHANGES TO OTHER ONGOING DOMVANALIMAB STUDIES BEYOND UPPER GASTROINTESTINAL PROGRAM</p></li><li><p>GILEAD - NO NEW SAFETY FINDINGS FOR COMBINATION OF DOMVANALIMAB PLUS ZIMBERELIMAB</p></li></ul><p>Further company coverage: <span>GILD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999015978.USD","symbol_name":"利安颠覆性创新基金A","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1JB:1","article_id":"2590350164","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590350164","pubTimestamp":1765546246,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 StudyDec 12 (Reuters) - Gilead Sciences Inc GILD.O:GILEAD: DISCONTINUATION OF PHASE 3 STAR-221 STUDYGILEAD: DISCONTINUATION DECISION BASED ON RECOMMEN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999015978.USD":"利安颠覆性创新基金A","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4139":"生物科技","LU0882574055.USD":"富达全球健康医疗A ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4566":"资本集团","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4578":"CAR-T","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4568":"美国抗疫概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4583":"猴痘概念","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK4532":"文艺复兴科技持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","GILD":"吉利德科学","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"简介-吉利德：停止3期STAR-221研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 StudyDec 12 (Reuters) - Gilead Sciences Inc GILD.O:GILEAD: DISCONTINUATION OF PHASE 3 STAR-221 STUDYGILEAD: DISCONTINUATION DECISION BASED ON RECOMMENDATION FROM INDEPENDENT DATA MONITORING COMMITTEEGILEAD -  IN INTERIM ANALYSIS, COMBINATION OF DOMVANALIMAB PLUS ZIMBERELIMAB & CHEMOTHERAPY DID NOT IMPROVE OS RELATIVE TO NIVOLUMAB PLUS CHEMOTHERAPYGILEAD: NO CHANGES TO OTHER ONGOING DOMVANALIMAB STUDIES BEYOND UPPER GASTROINTESTINAL PROGRAMGILEAD - NO NEW SAFETY FINDINGS FOR COMBINATION OF DOMVANALIMAB PLUS ZIMBERELIMABFurther company coverage: GILD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590350164","isCrawlerRequest":true}